tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics
PremiumRatingsPromising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics
1M ago
Aardvark Therapeutics initiated with a Buy at Stifel
Premium
The Fly
Aardvark Therapeutics initiated with a Buy at Stifel
1M ago
Buy Rating for Aardvark Therapeutics: ARD-101’s Potential in Prader-Willi Syndrome Treatment
Premium
Ratings
Buy Rating for Aardvark Therapeutics: ARD-101’s Potential in Prader-Willi Syndrome Treatment
1M ago
Aardvark Therapeutics Advances Clinical Trials and Financials
PremiumCompany AnnouncementsAardvark Therapeutics Advances Clinical Trials and Financials
2M ago
Aardvark Therapeutics price target lowered to $19 from $20 at RBC Capital
Premium
The Fly
Aardvark Therapeutics price target lowered to $19 from $20 at RBC Capital
3M ago
Aardvark Therapeutics reports Q2 EPS (66c), consensus (60c)
Premium
The Fly
Aardvark Therapeutics reports Q2 EPS (66c), consensus (60c)
3M ago
Aardvark Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe FlyAardvark Therapeutics initiated with a Buy at H.C. Wainwright
4M ago
Aardvark Therapeutics participates in 2025 United in Hope Conference
Premium
The Fly
Aardvark Therapeutics participates in 2025 United in Hope Conference
4M ago
Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO
Premium
The Fly
Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100